214 related articles for article (PubMed ID: 30582658)
41. Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.
Ishihara S; Yamamoto H; Iwasaki T; Toda Y; Yamamoto T; Yoshimoto M; Ito Y; Susuki Y; Kawaguchi K; Kinoshita I; Yamada Y; Kohashi K; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Kakuda Y; Nakashima Y; Oda Y
Mod Pathol; 2022 May; 35(5):640-648. PubMed ID: 34785767
[TBL] [Abstract][Full Text] [Related]
42. Gene fusions PAFAH1B1-USP6 and RUNX2-USP6 in aneurysmal bone cysts identified by next generation sequencing.
Warren M; Xu D; Li X
Cancer Genet; 2017 Apr; 212-213():13-18. PubMed ID: 28449806
[TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical correlates of recurrent genetic alterations in sarcomas.
Anderson WJ; Hornick JL
Genes Chromosomes Cancer; 2019 Feb; 58(2):111-123. PubMed ID: 30382607
[TBL] [Abstract][Full Text] [Related]
44. Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.
Li Z; Stölzel F; Onel K; Sukhanova M; Mirza MK; Yap KL; Borinets O; Larson RA; Stock W; Sasaki MM; Joseph L; Raca G
Leukemia; 2015 Oct; 29(10):2113-6. PubMed ID: 25787914
[No Abstract] [Full Text] [Related]
45. L-type amino acid transporter-1 and CD98 expression in bone and soft tissue tumors.
Koshi H; Sano T; Handa T; Yanagawa T; Saitou K; Nagamori S; Kanai Y; Takagishi K; Oyama T
Pathol Int; 2015 Sep; 65(9):460-7. PubMed ID: 26134029
[TBL] [Abstract][Full Text] [Related]
46. Dentine matrix protein 1 (DMP-1) is a marker of bone-forming tumours.
Kashima TG; Dongre A; Oppermann U; Athanasou NA
Virchows Arch; 2013 May; 462(5):583-91. PubMed ID: 23559304
[TBL] [Abstract][Full Text] [Related]
47. [The study of the value of H3F3A G34W immunohistochemical staining in the diagnosis of giant cell tumor of bone].
Bai YQ; Yang TT; Zhang HZ
Zhonghua Bing Li Xue Za Zhi; 2019 Jul; 48(7):531-536. PubMed ID: 31288308
[No Abstract] [Full Text] [Related]
48. Loss of NF2 defines a genetic subgroup of non-FOS-rearranged osteoblastoma.
Saba KH; Cornmark L; Hofvander J; Magnusson L; Nilsson J; van den Bos H; Spierings DC; Foijer F; Staaf J; Brosjö O; Sumathi VP; Lam SW; Szuhai K; Bovée JV; Kovac M; Baumhoer D; Styring E; Nord KH
J Pathol Clin Res; 2020 Oct; 6(4):231-237. PubMed ID: 32542935
[TBL] [Abstract][Full Text] [Related]
49. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
50. Next-generation sequencing entering the clinical arena.
Haas J; Katus HA; Meder B
Mol Cell Probes; 2011; 25(5-6):206-11. PubMed ID: 21914469
[TBL] [Abstract][Full Text] [Related]
51. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
52. Benign cartilaginous tumors of bone: from morphology to somatic and germ-line genetics.
Romeo S; Hogendoorn PC; Dei Tos AP
Adv Anat Pathol; 2009 Sep; 16(5):307-15. PubMed ID: 19700940
[TBL] [Abstract][Full Text] [Related]
53. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
54. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.
Groisberg R; Roszik J; Conley A; Patel SR; Subbiah V
Curr Oncol Rep; 2017 Oct; 19(12):78. PubMed ID: 29030741
[TBL] [Abstract][Full Text] [Related]
55. Soft-tissue and bone tumors about the foot and ankle.
Walling AK; Gasser SI
Clin Sports Med; 1994 Oct; 13(4):909-38. PubMed ID: 7805113
[TBL] [Abstract][Full Text] [Related]
56. Cartilage-forming tumors.
Qasem SA; DeYoung BR
Semin Diagn Pathol; 2014 Jan; 31(1):10-20. PubMed ID: 24680178
[TBL] [Abstract][Full Text] [Related]
57. Differential diagnosis of pedal osseous neoplasms.
Wu KK
Clin Podiatr Med Surg; 1993 Oct; 10(4):683-715. PubMed ID: 8221546
[TBL] [Abstract][Full Text] [Related]
58. Discovered on gastrointestinal stromal tumour 1 (DOG1): a useful immunohistochemical marker for diagnosing chondroblastoma.
Akpalo H; Lange C; Zustin J
Histopathology; 2012 Jun; 60(7):1099-106. PubMed ID: 22335248
[TBL] [Abstract][Full Text] [Related]
59. [Classification of primary bone tumors].
Vinogradova TP
Arkh Patol; 1971; 33(8):12-9. PubMed ID: 4945623
[No Abstract] [Full Text] [Related]
60. The pericentromeric inversion, inv (6)(p25q13), is a novel diagnostic marker in chondromyxoid fibroma.
Granter SR; Renshaw AA; Kozakewich HP; Fletcher JA
Mod Pathol; 1998 Nov; 11(11):1071-4. PubMed ID: 9831204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
